FY2026 Q1 earnings supplement. Includes year-over-year comparisons of net sales and key profit indicators, segment trends, and full-year guidance; focuses on detailed financial data and future outlook.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4584","jir_company_name":"Kidswell Biotech Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4584-20260813-03.pdf","jir_short_summary":"FY2026 Q1 earnings supplement. Includes year-over-year comparisons of net sales and key profit indicators, segment trends, and full-year guidance; focuses on detailed financial data and future outlook.","jir_summary":"### Overview of Results\nThis document is the FY2026 Q1 consolidated earnings supplement, showing a 74% year-over-year increase in net sales, 73% in gross profit, and 117% in operating income. It discloses segment contributions, cost structure details, and the breakdown of R&D and SG&A expenses, highlighting improvements in product portfolio and effective cost management.\n\n### Outlook and Investor Impact\nThe outlook discusses factors affecting full-year sales and profit guidance, along with cost reduction measures and optimization of logistics and manufacturing capabilities. For investors, the short-term growth trend, long-term R&D investment balance, and cash flow improvement are key points.","jir_financial_highlights":"Net Sales: 1,269,509 (thousand yen) (YoY 74%)\nGross Profit: 431,389 (YoY 73%)\nOperating Income: 216,506 (YoY 117%)","jir_category":"","jir_hashtags":"#ShareBuybackRelated, #ExecutiveAppointmentsRelated","jir_key_figures":"Net Sales: 1,269,509 thousand yen (YoY +74%)\nGross Profit: 431,389 thousand yen (YoY +73%)\nOperating Income: 216,506 thousand yen (YoY +117%)","jir_meta_title":"\u3010Kidswell Biotech\u30112026 Q1 Earnings Supplement \u2014 Strength in Net Sales and Profits, Full-Year Outlook","jir_meta_description":"Kidswell Biotech 2026 Q1 earnings supplement. Summary of drivers behind increases in net sales and operating income, segment trends, and outlook. Key indicators and guidance investors want.","jir_og_title":"\u3010Kidswell Biotech\u3011Earnings Supplement: Q1 YoY Large Increases in Revenue and Profit","jir_og_description":"Earnings supplement for FY2026 Q1. Explains substantial increases in net sales and profits, segment contributions, and outlook. Summary of key points for investors.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend\", \"jir_chart_json_data\": \"Unknown\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"Unknown\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Net Sales\", \"jir_chart_json_data\": \"Unknown\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Profit Margin Analysis\", \"jir_chart_json_data\": \"Unknown\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"table\", \"jir_chart_title\": \"Forecast vs Actual\", \"jir_chart_json_data\": \"Unknown\"}]","ir_related_company":58797,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-103555","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n